Imidazole → (+/-)-(3R,4R)-benzyl 4-((tert-butyldimethylsilyl)oxy)-3-morpholinopiperidine-1-carboxylate

HRID 921678Notizen

Reaktionsgleichung

Reaktionsgleichung von HRID 921678
[CH:1]12[O:7][CH:6]1[CH2:5][CH2:4][N:3]([C:8]([O:10][CH2:11][C:12]1[CH:17]=[CH:16][CH:15]=[CH:14][CH:13]=1)=[O:9])[CH2:2]2.[NH:18]1[CH2:23][CH2:22][O:21][CH2:20][CH2:19]1.Cl([O-])(=O)(=O)=O.[Li+].N1C=CN=C1.[C:35]([Si:39]([CH3:42])([CH3:41])Cl)([CH3:38])([CH3:37])[CH3:36]>C(#N)C.ClCCl>[Si:39]([O:7][C@@H:6]1[CH2:5][CH2:4][N:3]([C:8]([O:10][CH2:11][C:12]2[CH:17]=[CH:16][CH:15]=[CH:14][CH:13]=2)=[O:9])[CH2:2][C@H:1]1[N:18]1[CH2:23][CH2:22][O:21][CH2:20][CH2:19]1)([C:35]([CH3:38])([CH3:37])[CH3:36])([CH3:42])[CH3:41].[Si:39]([O:7][C@H:1]1[C@H:6]([N:18]2[CH2:23][CH2:22][O:21][CH2:20][CH2:19]2)[CH2:5][CH2:4][N:3]([C:8]([O:10][CH2:11][C:12]2[CH:17]=[CH:16][CH:15]=[CH:14][CH:13]=2)=[O:9])[CH2:2]1)([C:35]([CH3:38])([CH3:37])[CH3:36])([CH3:42])[CH3:41]

Komponenten

9

Edukt 5

HCID 795ImidazoleHCID 8083MorpholineHCID 28928tert-Butyldimethylsilyl chlorideHCID 13186888Benzyl 7-oxa-3-azabicyclo[4.1.0]heptane-3-carboxylateHCID 23665649Lithium perchlorate

Produkt 2

HCID 86708547(+/-)-(3R,4R)-benzyl 4-((tert-butyldimethylsilyl)oxy)-3-morpholinopiperidine-1-carboxylateHCID 86708548(+/-)-(3R,4R)-benzyl 3-((tert-butyldimethylsilyl)oxy)-4-morpholinopiperidine-1-carboxylate

Reagenzien, Katalysatoren, Lösungsmittel 2

HCID 6342AcetonitrileLösungsmittelHCID 6344DichloromethaneLösungsmittel

Versuchsvorschrift

A mixture of benzyl 7-oxa-3-azabicyclo[4.1.0]heptane-3-carboxylate (prepared according to a published literature procedure: Fink, Brian, et al., WO 2005/066176, 700 mg, 3.00 mmol), morpholine (0.581 mL, 6.00 mmol), and lithium perchlorate (639 mg, 6.00 mmol) in acetonitrile (10 mL) was heated at 80° C. for 4 h. Solvent was evaporated and the crude intermediate was dissolved in dichloromethane (10 mL), imidazole (654 mg, 9.60 mmol) and tert-butyldimethylchlorosilane (1357 mg, 9.00 mmol) were added. The reaction mixture was stirred at room temperature overnight. The reaction was diluted with dichloromethane and washed with water and brine, dried over sodium sulfate, filtered, and concentrated. The crude product was purified by flash chromatography on silica gel using an automated ISCO system (220 g gold column, eluting with 5-30% ethyl acetate/hexanes) to give (+/−)-(3R,4R)-benzyl 4-((tert-butyldimethylsilyl)oxy)-3-morpholinopiperidine-1-carboxylate (Isomer A, 0.39 g) as a colorless oil and (+/−)-(3R,4R)-benzyl 3-((tert-butyldimethylsilyl)oxy)-4-morpholinopiperidine-1-carboxylate (Isomer B, 0.43 g) as a colorless oil. The structures were confirmed by NMR studies (1H-1D, 13C-1D, COSY, NOESY, dept-1H-13C-HSQC, 1H-13C-HMBC).

Aufarbeitung

  1. customprepared
  2. customSolvent was evaporated
  3. dissolutionthe crude intermediate was dissolved in dichloromethane (10 mL)
  4. washwashed with water and brine
  5. dry with materialdried over sodium sulfate
  6. filtrationfiltered
  7. concentrationconcentrated
  8. customThe crude product was purified by flash chromatography on silica gel using
  9. washan automated ISCO system (220 g gold column, eluting with 5-30% ethyl acetate/hexanes)

Quellen und Nachweise

ORD-Eintrag
ord-2a104a605ce34822b68da8f8bae057df
Quelldatensatz
uspto-grants-2016_03
Patentnummer
US09273057B2

Notizen zur Reaktion

Wird geladen…